Works cited by this work

206 works

Work: Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders

1. The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy

   Shuguang Zhang, Wen‐Ying Chen, Jihong Zhou +5

   Review article20257 citations

   ABIABI:AkademIndex/openalex/2026.other.340938

2. Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies

   Ding-Ya Sun, Yijie Hu, Xin Li +3

   Review article20247 citations

   ABIABI:AkademIndex/openalex/2026.other.462660

3. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies

   Xinyi Xiao, Shengkang Huang, Sifei Chen +4

   Review article20215 citations

   ABIABI:AkademIndex/openalex/2026.other.102897

4. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

   Nikhil C. Munshi, Larry D. Anderson, Nina Shah +25

   Article20215 citations

   ABIABI:AkademIndex/openalex/2026.other.296878

5. Multidrug resistance in cancer: role of ATP–dependent transporters

   Michael M. Gottesman, Tito Fojo, Susan E. Bates

   Review article20024 citations

   ABIABI:AkademIndex/openalex/2026.other.719147

6. AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions

   Chou‐Yi Hsu, Shavan Askar, Samer Saleem Alshkarchy +7

   ArticleRadiomics and Machine Learning in Medical ImagingClinical and Experimental Medicine20253 citations

   ABIABI:AkademIndex/openalex/2025.article.000015

7. Harnessing bacteria for tumor therapy: Current advances and challenges

   Lina Guo, Jinsong Ding, Wenhu Zhou

   Article20233 citations

   ABIABI:AkademIndex/openalex/2026.other.326775

8. Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma

   Sylvain Simon, Stanley R. Riddell

   Other20203 citations

   ABIABI:AkademIndex/openalex/2026.other.340871

9. Precision sniper for solid tumors: CAR-NK cell therapy

   Sisi Li, Jiajie Jing, Yueming Chen +6

   Review article20253 citations

   ABIABI:AkademIndex/openalex/2026.other.340953

10. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

    Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani +33

    Article20213 citations

    ABIABI:AkademIndex/openalex/2026.other.475845

11. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

    Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos +80

    Review article20223 citations

    ABIABI:AkademIndex/openalex/2026.other.480204

12. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma

    Margot J. Pont, Tyler Hill, Gabriel O. Cole +14

    Article20192 citations

    ABIABI:AkademIndex/openalex/2026.other.020527

13. Multi-omics based and AI-driven drug repositioning for epigenetic therapy in female malignancies

    Annamaria Salvati, Viola Melone, Alessandro Giordano +12

    Review article20252 citations

    ABIABI:AkademIndex/openalex/2026.other.065099

14. GPRC5D-Targeted CAR T Cells for Myeloma

    Sham Mailankody, Sean M. Devlin, Jonathan Landa +35

    Article20222 citations

    ABIABI:AkademIndex/openalex/2026.other.082883

15. Off-the-Shelf Chimeric Antigen Receptor T Cells

    Norihiro Watanabe, Maksim Mamonkin

    Review article20212 citations

    ABIABI:AkademIndex/openalex/2026.other.121403

16. Untitled

    Other2 citations

    ABIABI:AkademIndex/openalex/2026.other.462627

17. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    Michèle Cavo, Evangelos Terpos, Cristina Nanni +25

    Review article20172 citations

    ABIABI:AkademIndex/openalex/2026.other.466312

18. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing

    Sumin Jo, Shipra Das, Alan F. Williams +19

    Article20222 citations

    ABIABI:AkademIndex/openalex/2026.other.475864

19. Liquid chromatography–tandem mass spectrometry for clinical diagnostics

    Stefani N. Thomas, Deborah French, Paul J. Jannetto +2

    Review article20222 citations

    ABIABI:AkademIndex/openalex/2026.other.478800

20. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

    Robert A. Kyle, Ellen D. Remstein, Terry M. Therneau +9

    Article20072 citations

    ABIABI:AkademIndex/openalex/2026.other.480082

21. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

    Joaquín Martínez‐López, Juan José Lahuerta, François Pépin +21

    Article20142 citations

    ABIABI:AkademIndex/openalex/2026.other.480111

22. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

    S. Vincent Rajkumar, Robert A. Kyle, Terry M. Therneau +7

    Article20052 citations

    ABIABI:AkademIndex/openalex/2026.other.480117

23. High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes

    Yinlei Bai, Kwan Yeung Wong, Tsz Kin Fung +1

    Other20162 citations

    ABIABI:AkademIndex/openalex/2026.other.480133

24. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

    Leo Rasche, Shweta S. Chavan, Owen Stephens +19

    Article20172 citations

    ABIABI:AkademIndex/openalex/2026.other.480144

25. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Elı́as Campo, Elaine S. Jaffe, James R. Cook +70

    Article20222 citations

    ABIABI:AkademIndex/openalex/2026.other.480200